Long-term outcomes of cytomegalovirus reactivation in patients with moderate to severe ulcerative colitis: A multicenter study

Gut and Liver

Volumn 8, Issue 6, 2014, Pages 643-647

  Kim, You Sun ^a,k   Kim, Young Ho ^b,k   Kim, Joo Sung ^c,k   Jeong, Seong Yeon ^a   Park, Soo Jeong ^d,k   Hee Cheon, Jae ^d,k   Ye, Byong Duk ^e,k   Jung, Sung Ae ^f,k   Park, Young Sook ^g,k   Choi, Chang Hwan ^h,k   Kim, Kyeung Ok ^i,k   Jang, Byung Ik ^i,k   Han, Dong Soo ^j,k   Yang, Suk Kyun ^e,k   Kim, Won Ho ^d,k  

^a Inje University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

^f Ewha Womans University School of Medicine   (South Korea)

^g Eulji University   (South Korea)

^h Chung Ang University College of Medicine   (South Korea)

ⁱ Yeungnam University College of Medicine   (South Korea)

^j Hanyang University College of Medicine   (South Korea)

^k Department of Internal Medicine IBD Study Group of the Korean Association for the Study of Intestinal Diseases   (South Korea)

more..

Author keywords

Colectomy; Colitis; Cytomegalovirus; Ganciclovir; Ulcerative

Indexed keywords

GANCICLOVIR; INFLIXIMAB; STEROID; ANTIVIRUS AGENT;

COLON RESECTION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; RECURRENCE RISK; RECURRENT VIRUS INFECTION; RELAPSE; REMISSION; RETROSPECTIVE STUDY; STEROID THERAPY; ULCERATIVE COLITIS; VIRUS REACTIVATION; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; COLITIS, ULCERATIVE; COMPLICATION; CYTOMEGALOVIRUS INFECTIONS; LONGITUDINAL STUDY; MULTICENTER STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UTILIZATION; VIRUS ACTIVATION;

ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; COLECTOMY; COLITIS, ULCERATIVE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; LONGITUDINAL STUDIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84908686191     PISSN: 19762283     EISSN: 20051212     Source Type: Journal    
DOI: 10.5009/gnl13427     Document Type: Conference Paper

References (21)

1. de Jong MD, Galasso GJ, Gazzard B, et al. Summary of the II International Symposium on Cytomegalovirus. Antiviral Res 1998;39:141-162.
2. Goodgame RW. Gastrointestinal cytomegalovirus disease. Ann Intern Med 1993;119:924-935.
3. Soderberg-Naucler C. Human cytomegalovirus persists in its host and attacks and avoids elimination by the immune system. Crit Rev Immunol 2006;26:231-264.
4. Söderberg-Nauclér C, Fish KN, Nelson JA. Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J Clin Invest 1997;100:3154-3163.
5. Nguyen M, Bradford K, Zhang X, Shih DQ. Cytomegalovirus reactivation in ulcerative colitis patients. Ulcers 2011;2011. pii: 282507.
6. Domènech E, Vega R, Ojanguren I, et al. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis 2008;14:1373-1379.
7. Wada Y, Matsui T, Matake H, et al. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment. Dis Colon Rectum 2003;46:S59-S65.
8. Criscuoli V, Casà A, Orlando A, et al. Severe acute colitis associated with CMV: a prevalence study. Dig Liver Dis 2004;36:818-820.
9. Cottone M, Pietrosi G, Martorana G, et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 2001;96:773-775.
10. Kim YS, Kim YH, Kim JS, et al. The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study. J Clin Gastroenterol 2012;46:51-56.
11. Al-Zafiri R, Gologan A, Galiatsatos P, Szilagyi A. Cytomegalovirus complicating inflammatory bowel disease: a 10-year experience in a community-based, university-affiliated hospital. Gastroenterol Hepatol (N Y) 2012;8:230-239.
12. Kim O, Kim SS, Choi BS, et al. Consistency of the low seroprevalence of human herpesvirus 8 and the rarity of Kaposi's sarcoma in South Korea. J Bacteriol Virol 2001;31:275-279.
13. Yi F, Zhao J, Luckheeram RV, et al. The prevalence and risk factors of cytomegalovirus infection in inflammatory bowel disease in Wuhan, Central China. Virol J 2013;10:43.
14. Dimitroulia E, Spanakis N, Konstantinidou AE, Legakis NJ, Tsakris A. Frequent detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease. Inflamm Bowel Dis 2006;12:879-884.
15. Inoue K, Wakabayashi N, Fukumoto K, et al. Toxic megacolon associated with cytomegalovirus infection in a patient with steroidnaïve ulcerative colitis. Intern Med 2012;51:2739-2743.
16. Pfau P, Kochman ML, Furth EE, Lichtenstein GR. Cytomegalovirus colitis complicating ulcerative colitis in the steroid-naive patient. Am J Gastroenterol 2001;96:895-899.
17. Kim YS, Kim YH, Kim JS, et al. Cytomegalovirus infection in patients with new onset ulcerative colitis: a prospective study. Hepatogastroenterology 2012;59:1098-1101.
18. Nakase H, Honzawa Y, Toyonaga T, et al. Diagnosis and treatment of ulcerative colitis with cytomegalovirus infection: importance of controlling mucosal inflammation to prevent cytomegalovirus reactivation. Intest Res 2014;12:5-11.
19. Park SH, Yang SK, Hong SM, et al. Severe disease activity and cytomegalovirus colitis are predictive of a nonresponse to infliximab in patients with ulcerative colitis. Dig Dis Sci 2013;58:3592-3599.
20. Ayre K, Warren BF, Jeffery K, Travis SP. The role of CMV in steroid-resistant ulcerative colitis: a systematic review. J Crohns Colitis 2009;3:141-148.
21. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3:47-91.